Blood­ied Cel­gene posts promis­ing ozan­i­mod PhI­II MS da­ta, but is it re­al­ly a $6 bil­lion drug?

Cel­gene pumped out its Phase III da­ta on its block­buster con­tender ozan­i­mod over the week­end, of­fer­ing some en­cour­ag­ing com­par­isons with Avonex in treat­ing pa­tients with re­laps­ing mul­ti­ple scle­ro­sis. But some of these num­bers will like­ly trig­ger some sec­ond guess­ing about the drug’s peak sales abil­i­ty af­ter Cel­gene paid $7.2 bil­lion to get its hands on the drug.

In­ves­ti­ga­tors re­cruit­ed 1,346 pa­tients for the SUN­BEAM tri­al, post­ing sta­tis­ti­cal­ly sig­nif­i­cant scores for the an­nu­al­ized re­lapse rate. But in a pooled analy­sis of SUN­BEAM and RA­DI­ANCE Part B stud­ies, their drug did not hit the goal for the time to 3-month con­firmed dis­abil­i­ty pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER